A patient who has had an MI is taking a beta-blocker.
What is the main benefit of beta-blocker therapy for this patient?

Choice A rationale

Kava, despite being a natural product, is not safe for everyone. It has been associated with a significant risk of severe liver damage, including hepatitis, cirrhosis, and liver failure, even with moderate use. The active compounds, kavalactones, are metabolized by the liver and can cause hepatotoxicity, making it unsafe for individuals with pre-existing liver disease.

Choice B rationale

Kava is not a prescription medication in the United States or many other countries. It is widely available over-the-counter as a dietary supplement in various forms, such as capsules, powders, and teas. Its status as a supplement, rather than a drug, means it is not subject to the same strict regulations and oversight as prescription medications.

Choice C rationale

While some studies have explored kava's anxiolytic properties, it is not recommended for patients with depression. There is no strong evidence to support its use for this condition, and the potential for liver toxicity makes it a high-risk supplement. The risk of liver damage outweighs any potential benefit, especially given the availability of safer, effective antidepressant treatments.

Choice D rationale

The most appropriate response is to advise the patient to inform their healthcare provider. Kava can interact with many medications, particularly those metabolized by the liver, such as sedatives, anxiolytics, and antidepressants, increasing the risk of both drug toxicity and liver damage. A healthcare provider can assess for potential harmful interactions and advise on safe use.

Choice A rationale

Driving while taking benzodiazepines is unsafe because these medications are central nervous system depressants, causing sedation, dizziness, and impaired motor coordination and reaction time. This cognitive and psychomotor impairment significantly increases the risk of accidents. The patient's ability to safely operate a vehicle is compromised, making it dangerous to drive.

Choice B rationale

Combining benzodiazepines and alcohol is extremely dangerous due to their synergistic depressant effects on the central nervous system. Both substances bind to GABA receptors, enhancing the inhibitory neurotransmitter GABA's effects. This combination can lead to severe respiratory depression, profound sedation, coma, and even death.

Choice C rationale

Benzodiazepines, while used for insomnia, significantly alter the normal sleep cycle. They decrease the time to fall asleep and increase total sleep time, but they also decrease the amount of time spent in the deeper stages of sleep, particularly slow-wave and REM sleep. This disruption can lead to a less restorative sleep architecture, potentially causing daytime sleepiness.

Choice D rationale

Benzodiazepines are known for their sedative effects, which can persist beyond the intended sleep period, a phenomenon known as "hangover effect.”. This residual sedation is due to the drug's half-life and can lead to impaired alertness, drowsiness, and cognitive dysfunction the following day. This effect is particularly prominent with long-acting agents.

Choice E rationale

Alcohol is a central nervous system depressant, and its use with benzodiazepines, also CNS depressants, poses a significant risk. The combined effect can lead to an exaggerated and dangerous level of sedation, respiratory depression, and even fatal overdose. Patients should be explicitly warned against alcohol consumption while on this medication.

Choice F rationale

It is unsafe to drive while taking benzodiazepines because they are CNS depressants that cause sedation, impaired judgment, and decreased psychomotor skills. These effects directly compromise the patient's ability to operate a vehicle safely, increasing the risk of accidents. Patients should be advised to avoid driving and other activities requiring alertness.